Clin Endosc.  2024 Jul;57(4):549-551. 10.5946/ce.2023.186.

Long-term follow-up of patients developing gastric mucosal lesions after initiating the potassium-competitive acid blocker vonoprazan

• Kubo K
• Kimura N

• KMID: 2558114
• DOI: http://doi.org/10.5946/ce.2023.186

Figure

• 

  Fig. 1. Esophagogastroduodenoscopy (EGD). Case 1. EGD performed before initiation of vonoprazan treatment reveals an atrophic change in the antrum owing to past Helicobacter pylori infection, although no atrophic or mucosal changes are noted in the gastric body (A, B). EGD performed 1 and 2 years after initiation of vonoprazan treatment demonstrates newly appearing gastric cracked mucosa (GCM) (C–E) and multiple white spot (WS) and gastric polyps (GP) in the greater curvature of the lower gastric body on white-light imaging (WLI) (F), respectively. The GCM, WS, and GP observed on close-up WLI (G) are each highlighted as such on texture and color enhancement imaging mode 1 and narrow-band imaging (NBI) (H, I), respectively. Magnifying endoscopy with NBI indicates WS to be rich in microscopic vessels on the mucosal surface (J). Repeated EGD performed 1 year after switching from vonoprazan to esomeprazole demonstrates no change in GCM except for the disappearance of the WS and reduction of the GP size (K, L).

• 

  Fig. 2. Esophagogastroduodenoscopy (EGD). Case 2. EGD performed before initiation of vonoprazan treatment reveals a normal gastric mucosa with no atrophic or mucosal changes in the gastric body (A). EGD performed 2 years after vonoprazan initiation demonstrates newly appearing gastric cracked mucosa (GCM) and gastric polyps (GP) (B), and EGD performed 4 years later demonstrates enlarged GP and newly appearing multiple white spot (WS) in the greater curvature of the lower gastric body on white-light imaging (WLI) (C, D). The GCM and WS observed on close-up WLI (E) are highlighted on texture and color enhancement imaging mode 1 and narrow-band imaging (NBI) (F, G), respectively. Magnifying endoscopy with NBI indicates the WS to be rich in microscopic vessels on the mucosal surface (H). Repeat EGD performed 1 year after switching from vonoprazan to esomeprazole reveals no change in the GCM except for the disappearance of the WS and a slight decrease in the size of the GP (I, J).

• 

  Fig. 3. Pathological findings. A tissue biopsy from white spots reveals a mucus pool within a dilated duct, which tested positive for Alcian–periodic acid–Schiff staining. (A, B) Case 1, scale bar: 100 μm. (C, D) Case 2, scale bar: 500 μm.

Reference

1. Arikawa Y, Nishida H, Kurasawa O, et al. Discovery of a novel pyrrole derivative 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine fumarate (TAK-438) as a potassium-competitive acid blocker (P-CAB). J Med Chem. 2012; 55:4446–4456.

2. Parsons ME, Keeling DJ. Novel approaches to the pharmacological blockade of gastric acid secretion. Expert Opin Investig Drugs. 2005; 14:411–421.

3. Matsukawa J, Kogame A, Tagawa Y, et al. Radiographic localization study of a novel potassium-competitive acid blocker, vonoprazan, in the rat gastric mucosa. Dig Dis Sci. 2016; 61:1888–1894.

4. Miyamoto S, Matsuno Y, Kato M, et al. Parietal cell protrusions and dilated oxyntic glands from use of vonoprazan. Am J Gastroenterol. 2017; 112:1899–1901.

5. Kubo K, Kimura N, Matsuda S, et al. Vonoprazan-associated gastric mucosal redness: a report of four cases. Intern Med. 2020; 59:507–511.

6. Kubo K, Kimura N, Watanabe R, et al. Vonoprazan-associated gastric mucosal redness in non-Helicobacter pylori-infected and Helicobacter pylori-eradicated stomach. Case Rep Gastroenterol. 2021; 15:751–758.

7. Nishiyama N, Kobara H, Ayaki M, et al. White spot, a novel endoscopic finding, may be associated with acid-suppressing agents and hypergastrinemia. J Clin Med. 2021; 10:2625.

8. Yoshizaki T, Morisawa T, Fujinami M, et al. Propensity score matching analysis: incidence and risk factors for "stardust" gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther. 2021; 53:94–102.

9. Iwamuro M, Shiraha H, Okada H. Gastric polyps' regression after potassium-competitive acid blocker cessation. J Gen Fam Med. 2022; 23:358–359.

10. Goto C, Okimoto K, Matsusaka K, et al. Long-term vonoprazan administration causes gastric fundic gland-type hyperplastic polyps and chronic bleeding. Clin J Gastroenterol. 2023; 16:159–163.